[ CancerWeb Home
| Comments
| Up One Level ]
Original Summaries of Selected CANCERLIT Records
Two Protocols Using 5-Fluorouracil in Pancreatic Cancer Therapy
Last modified on:
Tuesday, April 20, 1999 11:52:30
Copyright © 1994-2009, Information Ventures, Inc.
Encouraging results were reported (Bronn; ICDB/95613601) from
a trial of concurrent continuous infusion of 5-fluorouracil and
cisplatin and hyperfractionated (more frequent than the
traditional five daily doses each week) radiotherapy in nine
unresectable pancreatic cancer patients, of whom four had liver
metastases. This study was performed at Wayne State University
and St. Joseph Mercy Hospital in Pontiac, Michigan and used
radiographic endpoints. Complete and partial regression of the
pancreatic mass was achieved in 88% of all patients, with
complete regression in 44%. Patients with liver metastases
exhibited 75% partial regression(3/4) of liver masses and
either complete or partial regression of the primary.
Progression of disease occurred in only 22% who had liver and
lung metastases. Responders achieved dramatic local response
with minimal side-effects.
Another protocol used 5-fluorouracil (600 mg/m2 iv),
mitomycin-C (10 mg/m2 bolus iv) on Day 1, weekly leucovorin
(400 mg iv), and alpha-interferon (alpha-IFN; 3 million units)
for metastatic adenocarcinoma of the pancreas (23 cases),
stomach (2) and esophagus(3). Treatment cycles were given every
six weeks. Twenty patients had liver metastases. Leucovorin
400 mg iv, 5FU and mitomycin-C iv were given on day 1. 5FU
and leucovorin were given weekly and alphaIFN was given subcutaneously
Monday-Wednesday-Friday at 3 million U. Cycles were repeated every six weeks with
evaluation after each cycle. This study from the National
Biotherapy Study Group Study in Franklin, Tennessee (Soori;
ICDB/95613728), concluded that the regimen had significant
efficacy in metastatic pancreatic carcinoma. Overall response
rate for the entire group was 37% for the evaluable pancreatic
cancer patients. Predominant side-effects were hematologic.
November, 1995
Copyright (c) 1994-2009, Information Ventures, Inc.
Mail us at: Customer-Service@infoventures.com
http://infoventures.com